本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Bionomics

0.010
0.000
07月25日 16:00 澳洲时间 延时15分钟
成交量:- -
成交额:- -
市值:1,468.74万
市盈率:-0.51
高:0.010
开:0.010
低:0.010
收:0.010
分时
5日
日K
周K
月K
季K
年K
1分
5分
10分
15分
30分
1小时
2小时
更多
分时
5日
日K
周K
月K
季K
年K
1分
5分
10分
15分
30分
1小时
2小时
数据加载中...

公司资料

公司名字:
Bionomics
交易所:
ASX
成立时间:
- -
员工人数:
- -
公司地址:
- -
邮编:
- -
电话:
- -
传真:
- -
简介:
Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia, France, and the United States. It operates through Drug Discovery and Development, and Contract Services segments. The company's lead product candidate includes BNC210, a negative allosteric modulator, which is in various clinical trials for the treatment of anxiety, panic, agitation, and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that targets cancer stem cells; and BNC105, a vascular disrupting agent for the treatment of cancer, as well as disrupts the blood vessels that nourish tumors in cancer treatment. In addition, the company offers contract research services. Bionomics Limited has a strategic partnership with Merck & Co., Inc. The company was incorporated in 1996 and is based in Thebarton, Australia.

如果下载按钮点击无跳转,请点击右上角菜单选择 “在浏览器打开”